<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="3081">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04394195</url>
  </required_header>
  <id_info>
    <org_study_id>PO20043*</org_study_id>
    <nct_id>NCT04394195</nct_id>
  </id_info>
  <brief_title>sFlt1: a Biomarker of Organ Dysfunction in Critically-ill Patients With COVID-19?</brief_title>
  <acronym>COVIDsFlt1</acronym>
  <official_title>sFlt1: a Biomarker of Organ Dysfunction in Critically-ill Patients With COVID-19?</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CHU de Reims</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>CHU de Reims</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Short description of the protocol intended for the lay public. Include a brief statement of
      the study hypothesis (Limit : 5000 characters) The management of critically-ill patients with
      organ failure due to COVID-19 represents a major healthcare burden. While endothelial
      inflammation has been reported in these patients, the pathophysiological mechanisms remain
      incompletely elucidated.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Extended description of the protocol, including more technical information (as compared to
      the Brief Summary) if desired. Do not include the entire protocol; do not duplicate
      information recorded in other data elements, such as eligibility criteria or outcome
      measures. (Limit : 32 000 characters)

      The soluble fms-like tyrosine kinase 1 (SFlt1) is the soluble form of VEGF-A receptor 1
      (VEGFR1). By linking VEGF-A with a high affinity, sFlt1 blocks the VEGF-A / VEFR1 axis and
      impairs endothelial homeostasis. Its production increases during inflammation. We hypothesize
      that sFlt1 is upregulated and correlates with endothelial dysfunction and outcomes in
      critically-ill patients with COVID-19.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 25, 2020</start_date>
  <completion_date type="Anticipated">September 1, 2020</completion_date>
  <primary_completion_date type="Anticipated">July 1, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Association between concentration of circulating sFlt1 and use of vasopressor</measure>
    <time_frame>14 days</time_frame>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">200</enrollment>
  <condition>CORONAVIRUS INFECTIONS</condition>
  <arm_group>
    <arm_group_label>patients with COVID-19 infection</arm_group_label>
    <description>patients with COVID-19 infection</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>measurement of circulating sFlt1 concentration</intervention_name>
    <description>blood circulating sFlt1 concentration will be determined</description>
    <arm_group_label>patients with COVID-19 infection</arm_group_label>
  </intervention>
  <biospec_retention>None Retained</biospec_retention>
  <biospec_descr>
    <textblock>
      blood
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        All adult patients with COVID-19 hospitalized in University Hospital of Reims
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient with documented COVID-19 (positive PCR)

          -  Hospitalized in University Hospital of Reims

          -  Patient or family who have previously consented

        Exclusion Criteria:

          -  Patient &lt;18 yo

          -  Patient not insured under the French social security
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Chu Reims</name>
      <address>
        <city>Reims</city>
        <zip>51092</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Damien JOLLY</last_name>
      <phone>326788472</phone>
      <phone_ext>33</phone_ext>
      <email>djolly@chu-reims.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>May 16, 2020</study_first_submitted>
  <study_first_submitted_qc>May 16, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 19, 2020</study_first_posted>
  <last_update_submitted>May 16, 2020</last_update_submitted>
  <last_update_submitted_qc>May 16, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 19, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronavirus Infections</mesh_term>
    <mesh_term>Severe Acute Respiratory Syndrome</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

